beta

AGEN

Agenus, Inc.

Agen

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.

Market Cap: 537 Million

Primary Exchange: NASDAQ

Website: http://www.agenusbio.com

Shares Outstanding: 137 Million

Float: 105 Million

Dividend: (%)

Beta: 1.26728638318325

Sector: Health Technology

Industry: Biotechnology

Ethical Flags

Animal testing

Longest drawdown: 1141 trading days

From: 2015-06-17 To: 2019-12-09

Lowest Point:

Agenus to Host Annual Meeting of Stockholders

via: PR Newswire at 2019-06-13 11:48:00:000

LEXINGTON, Mass. , June 13, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , invites investors and the general public to attend its annual meeting of stoc… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud